CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 125 enrolled
Drug / intervention
onabotulinumtoxinA +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01777620
NCT01777620Phase 4Completed

A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides

Allergan·interventional·Posted Jan 29, 2013·Updated Apr 17, 2019

In Brief

A Phase 4 clinical trial evaluating onabotulinumtoxinA and Normal Saline for Facial Rhytides. Completed, enrolled 125 participants across 1 site.

Detailed Summary

This is a safety and efficacy study of BOTOX® in subjects with facial rhytides (glabellar lines and crow's feet lines).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFacial Rhytides
CountriesCanada
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 29, 2013
Enrollment StartJan 31, 2013
Primary CompletionMay 29, 2013
Study CompletionJul 31, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.4 years ago

Interventions

onabotulinumtoxinAbiological

BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.

Normal Salinedrug

Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.